secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACCENDRA HEALTH INC/VA/ (ACH)
CIK:        0000075252
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000075252-23-000004
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Owens & Minor reports Q4 GAAP operating loss of $53.5M; launches cost-cutting program targeting $200M by 2025
--------------------------------------------------------------------------------

- Q4 revenue $2,551M, up 3.4% YoY; full-year revenue $9,955M, up 1.7%.
- Q4 GAAP net loss $58.0M ($0.77 loss per share); adjusted net income $21.7M ($0.28 per share).
- Patient Direct Q4 revenue up 135% (10.3% adjusted for Apria); full-year operating cash flow $325M.
- Operating Model Realignment Program targets $30M adjusted operating income in 2023, $200M by 2025, and $250-400M working capital benefit.
- Perry Bernocchi promoted to CEO of Patient Direct segment; Dan Starck named EVP Business Excellence, both effective March 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/75252/000007525223000004/0000075252-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/75252/000007525223000004/omi-20230228.htm
  HTML page:      https://secwatch.observer/filing/0000075252-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer